Unmodificated stepless regulation of CRISPR/Cas12a multi-performance
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Rong Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), College of Laboratory Medicine, Chongqing Medical Laboratory Micro…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
As CRISPR technology is promoted to more fine-divided molecular biology applications, its inherent performance finds it increasingly difficult to cope with diverse needs in these different fields, and how to more accurately control the performance has become a key issue to develop CRISPR technology to a new stage. Herein, we propose a CRISPR/Cas12a regulation strategy based on the powerful programmability of nucleic acid nanotechnology. Unlike previous difficult and rigid regulation of core components Cas nuclease and crRNA, only a simple switch of different external RNA accessories is required to change the reaction kinetics or thermodynamics, thereby finely and almost steplessly regulating multi-performance of CRISPR/Cas12a including activity, speed, specificity, compatibility, programmability and sensitivity. In particular, the significantly improved specificity is expected to mark advance the accuracy of molecular detection and the safety of gene editing. In addition, this strategy was applied to regulate the delayed activation of Cas12a, overcoming the compatibility problem of the one-pot assay without any physical separation or external stimulation, and demonstrating great potential for fine-grained control of CRISPR. This simple but powerful CRISPR regulation strategy without any component modification has pioneering flexibility and versatility, and will unlock the potential for deeper applications of CRISPR technology in many finely divided fields.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Clinical Laboratory Diagnostics (Chinese Ministry of Education), College of Laboratory Medicine, Chongqing Medical Laboratory Microfluidics and SPRi Engineering Research Center, Chongqing Medical Unive…
- The Center for Clinical Molecular Medical Detection, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
- Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
ORCID-Profile: Guoming Xie
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
Zitieren
APA
Zhao, R., Luo, W., Wu, Y., Zhang, L., Liu, X., Li, J., Yang, Y., Wang, L., Wang, L., Han, X., Wang, Z., Zhang, J., Lv, K., Chen, T., & Xie, G. (2023). Unmodificated stepless regulation of CRISPR/Cas12a multi-performance. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad748
Vancouver
Zhao R, Luo W, Wu Y, Zhang L, Liu X, Li J, et al. Unmodificated stepless regulation of CRISPR/Cas12a multi-performance. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad748
BibTeX
@article{Zhao2023,
author = {Zhao, Rong and Luo, Wang and Wu, You and Zhang, Li and Liu, Xin and Li, Junjie and Yang, Yujun and Wang, Li and Wang, Luojia and Han, Xiaole and Wang, Zhongzhong and Zhang, Jianhong and Lv, Ke and Chen, Tingmei and Xie, Guoming},
title = {Unmodificated stepless regulation of CRISPR/Cas12a multi-performance},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad748}
}
EUVIMED